Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Emerging Markets Report: By Any Measure

ORLANDO, FL / ACCESSWIRE / April 3, 2019 / By any measure, Spherix Incorporated (NASDAQ: SPEX) has had a very good year. It is not often one can say at their annual meeting that the Company posted a one-time gain of $7.5 million and p.s., our science looks like it restored mobility to a mouse paralyzed by Acute Lymphoblastic Leukemia. That's all.

With Spherix now booking total assets of $13.3 million, less than 9 million shares outstanding and zero debt, CEO Anthony Hayes has likely engendered some goodwill from his shareholder base.

And while the headlines for both those aforementioned significant events are eye-catching, remarkable even, the more measured prose of Spherix's recentshareholder letter may be equally compelling. But as with all things Spherix it takes a little digging, like a scratch-off lottery ticket.

Here are a few notes from the shareholder letter worth noting, following:

Via its pending CBM merger Spherix now is pursuing a remarkable portfolio of drug development rights from The University of Texas and Wake Forest. The mouse mover drug is just one among them. The letter actually announced previously unreported preclinical results that indicate one of the drugs in the CBM portfolio has potential applications beyond those originally announced.

There is significant progress being made in other oncological applications, again with big names like Wake Forest. Take a look at this brief video and contemplate for a moment the market size for what this drug could do if it continues to kill cancer cells through its potential path to FDA approval.

Spherix's outside the box investment in novel start-up Mellow is now more interesting given Mellow's pivot to everything instead of just scooters. Now, Mellow is focused on borrowing an array of items from locals taking ride share, to omni-share. Plus, the first launch just started in Washington, D.C., giving Mellow its first case study and/or proof of concept. Stay tuned there.

The shareholder letter also better details Spherix's investment in a privacy technology called DatChat. A little homework on DatChat shows a very interesting business model:

DatChat is a complete personal privacy platform where you are always in control, even after you hit SEND or SUBMIT. Mobile messaging, email and file storage are the first personal cyber-security sectors that DatChat is addressing with its unique proprietary technology. The DatChat's technology allows you to change the rights to your messages and personal information any time after you hit send or submit.

Starting with messaging, DatChat is a privacy platform which allows the option to erase or change how long your messages stay on another person's device. You are always in full control of your personal privacy with DatChat. When sending someone a message, you can wipe it from your phone and theirs at any time.

Unique to DatChat are features such as: Screenshot Protection, "Nuke" which allows the complete eradication of a conversation on everyone's device, multi-layered encryption and the DatChat Messaging Rights Control Platform.

For us at Emerging Markets Report, that technology fills a massive need we see in the marketplace. It's a sign-us-up moment that we like in our covered companies.

And most importantly, it's just the latest jewel in Hayes's perpetual efforts to be opportunity agnostic and to bring real value to the Company's bottom line over and over again.

By any measure, Spherix has proven that it has an eye for value.

About Spherix Incorporated

Spherix Incorporated is a technology development company committed to the fostering of innovative ideas. Spherix Incorporated was formed in 1967 as a scientific research company. Our activities generally include the acquisition and development of technology through internal or external research and development. In addition, we seek to acquire existing rights to intellectual property through the acquisition of already issued patents and pending patent applications, both in the United States and abroad. We may alone, or in conjunction with others, develop products and processes associated with technology development and monetizing related intellectual property.

About Emerging Markets Report:

Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php.

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

EMC has been paid 85,000 dollars for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. A contributor to this report (Integrity Media) receives $3,500 a month for a period of six months for investor relations and consulting services on the behalf of Spherix.

http://emergingmarketsllc.com/disclaimer.php

CONTACT:

Emerging Markets Consulting, LLC
Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com

SOURCE: Emerging Markets Report



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today